A multinational pharmaceutical company sought to assess KRAS competitors to inform their combination and development strategy.

• Created KRAS trial database to compare competitor approaches including indications, combinations, dosing and more
• Developed a pan-tumor heatmap and benchmarked clinical outcomes
• Analyzed combination approaches & digitized KM curves and synthesized KOL commentary

Our client used output from our analyses to inform its KRAS combination strategy and to help set TPP minimal and ideal development hurdles.